Personalized Medicine and Imaging DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Purpose: DNA methyltransferase 3A (DNMT3A) is one of the commonly mutated genes in acute myelogenous leukemia (AML). Reports on the prognostic significance ofDNMT3Amutations have been inconsistent, and most of the data are available only for patients 60 years of age or younger.We hypothesized that this inconsistency is due to an interaction between the dose of anthracycline used in induction therapy andDNMT3A status. We studied whether patients with DNMT3A-mutated AML treated with standard dose anthracyclines had an inferior survival compared with patients with other mutation profiles or those who received high-dose therapy. Experimental Design: A total of 152 patients in this retrospective cohort study (median age, 54 years) with de novo AML underwent induction therapy and next-generation sequencing of 33 commonly mutated genes in hematologic malignancies, including DNMT3A, FLT3-ITD, NPM1, and IDH1/2. Cox regression was used to know whether those with DNMT3A mutations who were treated with standard dose anthracycline had inferior survival. Results: DNMT3A mutations, found in 32% of patients, were not associated with an inferior survival. Dose escalation of anthracycline in the induction regimen was associated with improved survival in those with DNMT3A mutations but not thosewithwild-typeDNMT3A. PatientswithDNMT3Amutations who received standard dose induction had shorter survival time than other patient groups (10.1 months vs. 19.8 months, P 1⁄4 0.0129). This relationship remained significant (HR, 1.90; P 1⁄4 0.006) controlling for multiple variables. Conclusions: Patients with DNMT3A-mutated AML have an inferior survival when treated with standard-dose anthracycline induction therapy. This group should be considered for high-dose induction therapy. Clin Cancer Res; 21(7); 1614–20. 2015 AACR.